Printer Friendly

Research Report on China's Antidepressant Market, 2013-2017.

DUBLIN, June 12, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/b7j88d/research_report) has announced the addition of the "Research Report on China's Antidepressant Market, 2013-2017" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Oct. 10 is "World Mental Health Day". In 2012, its theme is "Depression: a Global Crisis". According to statistics from the United Nations, about 350 million people suffer from depression in the world. Approximately one million people commit suicide every year because of depression, thus depression becomes a health crisis worldwide.

In developed countries, the sales volume of medicines for depression and anxiety disorder amounts to 45% of market share of nervous centralis medicines. Depressant medicines and schizophrenia drugs totally account for 80% of world's mental disorder medicines. There are totally 50 to 60 varieties of antidepressants on the market or in development, which is more than therapeutic agents of schizophrenia. According to reports, the current eight best-selling antidepressants globally are Fluoxetine, Paroxetine, Sertraline, Fluvoxamine, Venlafaxine, Mirtazapine, Duloxetine and Amitriptyline, and the total sales amount exceeds 80% of global antidepressant market.

With the rapid development of economy, continuous improvement in people's living standards, continuously-intensified social competition, recombination of labour forces and changes in population and family structures, depression presents an obviously increasing trend in China. It is estimated that there are over 30 million depression patients in China, among which more than 90% cannot be promptly diagnosed and treated, causing deterioration of diseases and even serious consequences of committing suicide. Statistics show that committing suicide becomes an important cause of death among young adults aged between 15 and 34 in China. Among these crowds, depression patients account for about two-thirds.

At present, the market size of China's antidepressants is very small. In 2012, the market size of China's antidepressants in hospital medicines is only about CNY 3.2 billion, with an increase of 22.6% YOY. In terms of national medicine market, the antidepressant market is still in a small size on the whole. However, with the increasing recognition rate of doctors for depression and people's changes in treatment concepts, it is expected that the future potential of China's antidepressant market is fairly great. It is predicted that in the coming years, the annual growth rate of market size of China's antidepressants in hospital medicines will maintain over 20%.

The following information can be acquired through this report:

- Morbidity of China's Depression - Current Market of China's Antidepressants in Hospital Medicines - Competition in China's Antidepressant Market - Development Trends of Technologies and Market of China's Antidepressants

People working in the industries listed below are recommended to buy this report:

- Antidepressant Manufacturers - Pharmaceutical Trade Enterprises and Hospitals - Investors and Research Institutions Focusing on Pharmaceutical Industry

Key Topics Covered:

1 Overview on Antidepressants

2 Market Conditions of China's Antidepressants, 2011-2012

3 Analysis on Major Varieties of China's Antidepressants, 2011-2012

4 Reference Prices of China's Major Antidepressants, 2012

5 Prediction on Development of China's Antidepressants, 2013-2017

For more information visit http:/http://www.researchandmarkets.com/research/b7j88d/research_report

Research and Markets Laura Wood, Senior Manager. press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Healthcare and Medical Devices, Pharmaceuticals
COPYRIGHT 2013 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Geographic Code:4EUUK
Date:Jun 12, 2013
Words:765
Previous Article:Edison Reports on Low & Bonar's Intentions to Accelerate Growth in International Markets Including North America.
Next Article:GDS International Leads the Way for the Pharmaceutical Industry at its Upcoming NGP DD 30 Summit in Madrid.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters